Cell Therapy Consumables Market by Type of Consumable, Type of Cell Therapy, Scale of Operation, Type of End-User and Key Geographical Regions : Industry Trends and Global Forecasts, 2021 - 2031

INTRODUCTION
According to the US Food and Drug Administration (FDA), there has been an evident increase in the number of cell and gene therapy products being evaluated in early phases of development. This can further be validated by the observed upsurge in the number of investigational new drug (IND) applications. In fact, more than 800 IND applications have been filed for ongoing clinical studies, indicating remarkable scientific progress and therapeutic promise of these breakthrough drug candidates. However, manufacturing of cell therapies is a complex and capital-intensive process fraught with a wide range of challenges. Some of the key concerns of contemporary innovators include raw material supply constraints, current facility limitations, high cost of ancillary materials (buffers, growth factors and media) used in upstream processes, regulatory and compliance-related issues, and inconsistencies related to quality attributes of the final product. Further, the onset of recent COVID-19 pandemic has created additional challenges for therapy developers, in terms of procuring the required raw materials, by disrupting well-established supply chains.

Recent reports indicate that the global demand for human serum albumin (a key component of cell culture media for use in a multitude of therapeutic and emerging biotech areas) has increased at an annual rate of 10%-15%. , On the contrary, the use of animal components is highly disregarded by the US FDA, European Medicines Agency (EMA), and other regulatory bodies on the grounds that they pose an undesirable risk of transmitting infectious agents, such as prions (mad cow disease) and virus (HIV), as well as enable high batch-to-batch variation. Consequently, serum-free and xeno-free media have proven to be a promising alternative to serum derived components. In order to produce quality cellular therapies, several drug developers prefer to rely on third-party service providers for the supply of raw materials, such as cell culture medium, cell isolation kits and cell separation reagents. Presently, over 60 service providers are actively engaged in providing consumable / raw material products for the production of cell therapies. The current consolidated market landscape is primarily dominated by the presence of large players, capturing a substantial proportion of the market share. In the recent past, many of the aforementioned service providers have also forged strategic alliances and / or acquired other players, in order to further enhance their respective service offerings. Given that the demand for cell therapies is indubitably rising, the corresponding opportunity for cell therapy consumable service providers is expected to witness steady growth, over the next decade.

SCOPE OF THE REPORT
The “Cell Therapy Consumables Market by Type of Consumable (Kits, Media and Reagents), Type of Cell Therapy (Dendritic Cell Therapy, NK Cell Therapy, Stem Cell Therapy and T-Cell Therapy), Scale of Operation (Clinical and Commercial), Type of End-User (Industry and Non-Industry) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021 – 2031” report features an extensive study on the consumable providers within the cell therapy industry. The study also includes an elaborate discussion on the future potential of this evolving market.

Amongst other elements, the report features:
A detailed overview of the overall market landscape of players engaged in offering cell therapy consumables, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, number and location of consumable facilities, type of consumable (kits, media and reagents), type of cell therapy (dendritic cell therapy, NK cell therapy, stem cell therapy and T-cell therapy), application area (research use and therapeutic use), scale of operation (preclinical, clinical and commercial) and type of end-user (industry and non-industry).
An in-depth company competitiveness analysis of cell therapy consumable service providers based on their product portfolio strength (number of type of consumable, number of unique type of cell therapy, number of consumable facilities and application area), service strength (based on its experience and company size) and number of products offered.
A detailed brand positioning analysis of prominent industry players (shortlisted on the basis of strength of service portfolio), highlighting the current perceptions regarding their proprietary brands across different consumable classes.
Elaborate profiles of the key players offering cell therapy consumable products. Each profile features a brief overview of the company, details related to cell therapy consumable focused product portfolio, consumable facilities, recent developments and an informed future outlook.
An analysis of recent developments within the cell therapy consumable industry, highlighting information on several partnerships and collaborations, mergers and acquisitions, and expansion initiatives that have taken place in this domain, during the period 2016-2021.
A list of over 310 cell therapy developers that are anticipated to partner with cell therapy consumable providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development), manufacturing facilities and availability of other cell therapy capabilities.
An informed estimate of the annual demand for cell therapy consumables (in terms of volume of media required for total number of cells), based on type of cell therapy and key geographical regions.
An elaborate discussion on the future opportunities / trends within the cell therapy consumables market that are likely to influence the growth of this domain over the coming years.
An insightful discussion on how the recent COVID-19 pandemic is likely to impact the consumables market for cell therapies, along with information on the key initiatives undertaken by various service providers in order to overcome the challenges faced due to the pandemic.

One of the key objectives of the report was to estimate the existing market size and the future opportunity associated within the cell therapy consumables market, over the next decade. We have developed an informed estimate of the financial evolution of the market, over the period 2021-2031. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of consumable (kits, media and reagents), [B] type of cell therapy (dendritic cell therapy, NK cell therapy, stem cell therapy and T-cell therapy), [C] scale of operation (clinical and commercial), [D] type of end-user (industry and non-industry) and [E] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our forecast model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the industry’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary research. For all our projects, we have conducted interviews with various experts in this domain (academia, industry, medical practice and other associations) in order to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market till 2031, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED
• Who are the key players, across the world, engaged in offering consumables for cell therapies?
Which regions have emerged as key hubs in terms of cell therapy consumable related capabilities?
Which are the most popular media components used for cell therapy consumables?
What kind of partnership models are most commonly adopted by stakeholders engaged in this industry?
How is the recent COVID-19 pandemic likely to impact the consumables market for cell therapies?
What are the key challenges associated with cell therapy consumables?
What is the current, global demand (kits, media and reagents) for cell therapy consumables in the manufacturing process?
How is the current and future market opportunity likely to be distributed across key market segments?
What are the anticipated future trends related to consumables market for cell therapies?

CHAPTER OUTLINES
Chapter 2 is an executive summary of key insights captured in our research. It offers a high-level view on the current state of the cell therapy consumables market and its likely evolution in the short to mid-term and long-term.

Chapter 3 provides a general introduction to cell therapies. It further includes a detailed discussion on the development and manufacturing process of cell therapies, along with information on the role of raw materials in cell therapy manufacturing. Furthermore, it provides a brief overview of the different types of cell therapy consumables and key challenges associated with their development.

Chapter 4 provides a detailed overview of the cell therapy consumables landscape. It includes information related to over 60 industry players that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as year of establishment, company size, location of headquarters, location of consumable facilities, type of consumable (kits, media and reagents), type of cell therapy (dendritic cell therapy, NK cell therapy, stem cell therapy and T-cell therapy), application area (research use and therapeutic use), scale of operation (preclinical, clinical and commercial) and type of end-user (industry and non-industry).

Chapter 5 features an insightful company competitiveness analysis, highlighting prominent consumable service providers, taking into consideration service strength of a company (based on its experience and company size), product portfolio (number of type of consumable, number of unique type of cell therapy, number of consumable facilities and application area) and number of products.

Chapter 6 provides an elaborative brand positioning analysis of the leading industry players (shortlisted on the basis of strength of service portfolio), highlighting the current perceptions regarding their proprietary brands across different consumable classes.

Chapter 7 provides elaborate profiles of key service providers (shortlisted on the basis of the company competitiveness analysis) engaged in this domain. Each profile features a brief overview of the company, details related to cell therapy consumable focused product portfolio, consumable facilities, recent developments and an informed future outlook.

Chapter 8 provides detailed analysis of the recent developments and initiatives (partnerships and collaborations, mergers and acquisitions and expansions) that have been undertaken in the cell therapy consumable industry, during the period between 2016 and 2021.

Chapter 9 features an in-depth analysis of over 310 cell therapy developers that are anticipated to partner with cell therapy consumable providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development), manufacturing facilities and availability of other cell therapy capabilities.

Chapter 10 provides an informed estimate of the annual demand for cell therapy consumables (in terms of volume of media required for total number of cells), based on type of cell therapy and key geographical regions.

Chapter 11 presents an insightful market forecast analysis, highlighting the future potential of cell therapy consumables market till 2031. We have segmented the market on the basis of [A] type of consumable (kits, media and reagents), [B] type of cell therapy (dendritic cell therapy, NK cell therapy, stem cell therapy and T-cell therapy), [C] scale of operation (clinical and commercial), [D] type of end-user (industry and non-industry) and [E] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World).

Chapter 12 features an elaborate discussion on the future opportunities / trends within the cell therapy consumables market that are likely to influence the growth of this domain over the coming years.

Chapter 13 highlights the effects of the recent COVID-19 pandemic on the consumables market for cell therapies, along with information on the key initiatives undertaken by various service providers in order to overcome the challenges faced due to the pandemic.

Chapter 14 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the cell therapy consumables market, based on the research and analysis described in the previous chapters.

Chapter 15 is a collection of transcripts of interviews conducted with various stakeholders in the industry.

Chapter 16 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix that provides the list of companies and organizations mentioned in the report.